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Two investigational anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) -lactams, ceftaroline (a
cephalosporin) and ME1036 (a carbapenem), were subjected to susceptibility testing by reference broth
microdilution methods using 152 strains of community-acquired MRSA from the United States (47 medical
centers). Ceftaroline and ME1036 were 64- and >128-fold more potent than ceftriaxone, respectively. All
isolates had the Panton-Valentine leukocidin genes and staphylococcal cassette chromosomemec type IV, while
67.8% of isolates displayed pulsed-field gel electrophoresis clonal type USA300-0114.
Ceftaroline fosamil (formerly known as PPI-0903 and TAK-
599) is an N-phosphono-type prodrug cephalosporin (15). Its
active form, ceftaroline, is released in vivo upon the hydrolysis
of the phosphonate group (5). This cephem has documented
high affinity for penicillin binding protein 2a (PBP2a) and
potent in vitro activity against oxacillin (methicillin)-resistant
Staphylococcus aureus (MRSA) and many other gram-positive
organisms, while retaining activity against gram-negative bacilli
(6, 14, 15).
Staphylococcus spp., including MRSA and oxacillin-resistant
coagulase-negative staphylococci, appear to be particularly
susceptible to ceftaroline (MIC90, 0.25 to 2 g/ml) (5, 15).
Ceftaroline has also shown good activity against vancomycin-
nonsusceptible MRSA, a pathogen of concern that has been
increasingly documented in recent years (9, 16), and key res-
piratory pathogens such as Streptococcus pneumoniae and Hae-
mophilus influenzae. Ceftaroline has demonstrated bactericidal
activity and increased in vitro potency compared with currently
available cephalosporins against drug-resistant S. pneumoniae
strains (16).
The spectrum of activity of ceftaroline against gram-negative
bacteria is similar to those of the broad-spectrum cephalospo-
rins. Among the Enterobacteriaceae, the vast majority of
Citrobacter freundii (MIC90, 2 g/ml), non-extended-spectrum
-lactamase (ESBL)-producing Escherichia coli (MIC90, 0.12
g/ml) and Klebsiella pneumoniae (MIC90, 0.5 g/ml), Mor-
ganella morganii (MIC90, 0.12 g/ml), Proteus mirabilis (MIC90,
0.12 g/ml), and Serratia marcescens (MIC90, 2 g/ml) strains
are inhibited at2 g of ceftaroline/ml (15). However, like the
MICs of other broad-spectrum cephalosporins, ceftaroline
MICs for some Enterobacter cloacae, Proteus vulgaris, and
Providencia spp. strains and ESBL-producing strains regardless
of species were previously observed to be elevated (15).
ME1036 (formerly CP5609) is a novel parenteral carbap-
enem with a 7-acylated imidazo[5,1-b]thiazole-2-yl group at-
tached directly to the carbapenem moiety of the C-2 position
(9). ME1036 has demonstrated high affinity for altered staph-
ylococcal PBP2 and potent in vitro activity against MRSA.
This compound has also shown potent in vitro activities against
penicillin-resistant S. pneumoniae, H. influenzae, and Entero-
coccus faecalis. When tested against members of the Entero-
bacteriaceae, ME1036 is more active than ceftriaxone and other
broad-spectrum cephalosporins (including ceftaroline) due to
a higher level of resistance to hydrolysis by ESBLs and AmpC
-lactamases produced by these organisms (8, 9, 12).
The objective of the present study was to evaluate the in vitro
activities of these two novel -lactam compounds against com-
munity-acquired MRSA (CA-MRSA) strains isolated throughout
the United States.
(This study was presented in part at the 47th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Chi-
cago, IL, 17 to 20 September 2007.)
A collection of 152 strains from geographically diverse loca-
tions (47 medical centers) were selected from surveillance
programs in the United States to include well-characterized
CA-MRSA strains isolated in cases of human infection. The
isolates were collected in the period from 2000 to 2005. Re-
agent-grade ceftaroline and ME1036 compounds were pro-
vided by Cerexa, Inc. (Alameda, CA). Comparator agents were
purchased from Sigma Chemical Co. (St. Louis, MO) or ob-
tained from their respective manufacturers in the United
States. MICs were determined and interpreted by reference
broth microdilution methods according to procedures estab-
lished by the Clinical and Laboratory Standards Institute
(CLSI), formerly the National Committee for Clinical Labo-
ratory Standards (2, 3).
PCR amplification of Panton-Valentine leukocidin (PVL)
genes (lukF-PV and lukS-PV) was performed by previously de-
scribed procedures (10) with the following primers: luk-PV-F,
ATC ATT AGG TAA AAT GTC TGG ACA TGA TCC A, and
luk-PV-R, GCA TCA AST GTA TTG GAT AGC AAA AGC.
All PVL gene-positive isolates were characterized by the type of
staphylococcal cassette chromosome mec (SCCmec) element by
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using a multiplex PCR strategy (13). The primers amplified var-
ious DNA segments within the SCCmec elements that were char-
acteristic of each of the types I, II, III, and IV. The mecA gene was
amplified as part of the multiplex PCR to serve as an internal
control. PCR products were separated on 2% agarose gel in
Tris-acetate-EDTA buffer on a Criterion Sub-cell GT system
(Bio-Rad, Hercules, CA) and stained with ethidium bromide.
SCCmec types were assigned based on the numbers and sizes of
the amplicons obtained.
PVL gene-positive CA-MRSA isolates were subjected to
pulsed-field gel electrophoresis (PFGE) according to the pro-
cedure described by Tenover et al. (17). PFGE patterns were
compared to those of CA-MRSA clones prevalent in the
United States (17). The PFGE patterns were designated by a
capital letter (e.g., C, F, G, and K). Strains were assigned to the
same PFGE pattern only when all bands matched. When there
was a difference of one or two bands, the strains were classified
as a subtype or variant of the major type, and the subtype was
designated with the same capital letter used for the major type,
followed by an Arabic numeral (e.g., C1, C2, C3, etc.).
The in vitro activities of ceftaroline, ME1036, and comparator
agents are summarized in Table 1. Both ceftaroline and ME1036
were highly active against the collection of CA-MRSA strains
evaluated. Ceftaroline showed an MIC50 and an MIC90 of 0.5
g/ml, and the highest MIC was 1 g/ml; ME1036 showed an
MIC50 of 0.12 g/ml, an MIC90 of 0.25 g/ml, and a highest MIC
of only 0.5 g/ml.
All isolates appeared to be susceptible to imipenem (the high-
est MIC was 2 g/ml), clindamycin (all MICs were0.25 g/ml),
trimethoprim-sulfamethoxazole (all MICs were 0.25 g/ml),
linezolid (the highest MIC was 2 g/ml), daptomycin (the highest
MIC was 1 g/ml), and vancomycin (the highest MIC was 2
g/ml). Furthermore, the vast majority (90%) of strains tested
were susceptible to meropenem (98.0% of strains were suscepti-
ble), levofloxacin (92.8% of strains were susceptible), and tetra-
cycline (94.7% of strains were susceptible). In contrast, the vast
majority of strains were resistant to ceftriaxone, amoxicillin-cla-
vulanate, and erythromycin (Table 1).
Table 2 shows the MIC distributions for the -lactam com-
pounds evaluated in the study. The ceftaroline MIC range was
very narrow (0.25 to 1 g/ml), and the MIC for 148 strains
(97.4%) was 0.5 g/ml. ME1036 MICs ranged from 0.06 to
only 0.5 g/ml, with an MIC of 0.12 g/ml for 69.7% of strains.
Ceftriaxone and amoxicillin-clavulanate showed limited activ-
ity against these CA-MRSA strains, with MICs for 98.7% of
strains being greater than or equal to the respective resistance
breakpoint. On the other hand, the carbapenems imipenem
(MIC90, 0.5 g/ml) and meropenem (MIC90, 2 g/ml) were
very active in vitro against this collection of strains, even
though MRSA isolates are considered to be resistant to all
-lactams according to CLSI criteria (2).
All isolates showed positive PCR results for PVL genes and
SCCmec type IV. PCR screening for agr type was performed
with a selected group of 23 strains, and 22 of those exhibited
TABLE 1. In vitro activity of ceftaroline and ME1036 tested against a selected collection of 152 well-characterized CA-MRSA strains
Antimicrobial agent
MIC (g/ml)
% Of susceptible strains % Of resistant strains
50% 90% Range
ME1036 0.12 0.25 0.06–0.5 a —
Ceftaroline 0.5 0.5 0.25–1  —
Ceftriaxone 32 32 16–32 0.0 (0.0)b 98.7
Imipenem 0.5 0.5 0.5–2 100.0 (0.0)b 0.0
Meropenem 2 2 0.5–8 98.0 (0.0)b 0.0
Amoxicillin-clavulanate 8 8 2–8 1.3 (0.0)b 98.7
Erythromycin 8 8 2–8 1.3 98.0
Clindamycin 0.25 0.25 0.25 100.0 0.0
Levofloxacin 0.25 0.5 0.12–4 92.8 7.2
Tetracycline 0.5 0.5 0.5–16 94.7 4.6
Trimethoprim-sulfamethoxazole 0.25 0.25 0.25 100.0 0.0
Linezolid 2 2 1–2 100.0 —
Daptomycin 0.25 0.5 0.25–1 100.0 0.0
Vancomycin 1 1 0.5–2 100.0 0.0
a , no breakpoint has been established by the CLSI (2) for this category.
b The number in parentheses indicates the percentage of strains considered to be susceptible according to CLSI M100-S17 criteria.
TABLE 2. MIC distributions for ceftaroline, ME1036, and four other -lactams tested against a collection of 152 CA-MRSA strains isolated
in the United States
Antimicrobial agent
No. of strains (cumulative %) inhibited at a MIC (g/ml) of:
0.06 0.12 0.25 0.5 1 2 4 8 16
ME1036 16 (10.5) 106 (80.3) 26 (97.4) 4 (100.0) 0 (100.0) 0 (100.0) 0 (100.0) 0 (100.0) 0 (100.0)
Ceftaroline 0 (0.0) 0 (0.0) 1 (0.7) 148 (98.0) 3 (100.0) 0 (100.0) 0 (100.0) 0 (100.0) 0 (100.0)
Ceftriaxone 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.3)
Imipenem a   139 (91.4) 9 (97.4) 4 (100.0) 0 (100.0) 0 (100.0) 0 (100.0)
Meropenem    9 (5.9) 22 (20.4) 106 (90.1) 12 (98.0) 3 (100.0) 0 (100.0)
Amoxicillin-clavulanate   0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 2 (1.3) 121 (80.9) 
a , untested dilution concentration.
1154 NOTES ANTIMICROB. AGENTS CHEMOTHER.
agr type I, while the remaining strain exhibited agr type III. The
vast majority of strains (94.1%) showed the major PFGE type
C, which is equivalent to that presented by clone USA300 and
variants (17). USA300 is the most common CA-MRSA clone
reported in the United States. One hundred three strains
(67.8%) showed identical PFGE patterns that were equivalent
to that of the USA300-0114 clone. Forty other strains showed
recognized variations of the major PFGE pattern (one or two
bands different), comprising 14 subtypes. One of these sub-
types was observed in 19 strains, while the others were ob-
served in one (10 subtypes) to five isolates. Furthermore, seven
strains (4.6%) showed a major pattern (with three subtypes)
identical to that presented by clone USA400 (17).
Before the emergence and rapid dissemination of MRSA,
-lactams were the standard treatment for staphylococcal in-
fections (11). The safety and clinical efficacy of these antimi-
crobials were well recognized by physicians, but the perception
of the clinical utility of this class diminished with the increasing
prevalence of MRSA infections. Furthermore, due to some
reports of the clinical failure of treatment of MRSA infections
with -lactam antibiotics to which the infecting strain was
categorized as susceptible, MRSA has been considered resis-
tant to all -lactam antibiotics independent of the susceptibility
testing result (2). However, a series of cephems and carbap-
enems, including ceftaroline and ME1036, with anti-MRSA
activity due to potent binding to PBP2a are currently under
investigation (1). The anti-MRSA -lactams have demon-
strated excellent in vitro and in vivo bactericidal activity against
MRSA (including both CA-MRSA and hospital-associated
MRSA). These agents have the potential to restore physicians’
confidence in using -lactam antibiotics for the treatment of
MRSA infections.
CA-MRSA expressing the PVL has emerged as a serious
problem in the United States. CA-MRSA infections are in-
creasing in incidence in both urban and rural settings and
commonly affect the young and the healthy. Most infections
present as skin and soft-tissue infections, especially cellulitis,
abscesses, and folliculitis. However, a severe syndrome of lung
and septic joint involvement often affects children and young
adults and may be fatal (4). Thus, empirical antimicrobial
treatment of seriously ill patients with community- or hospital-
acquired infections that may be caused by S. aureus should
include a drug with anti-MRSA activity (7).
The results of this study showed that ceftaroline and
ME1036 were very active against a well-characterized collec-
tion of CA-MRSA isolates obtained from patients throughout
the United States. The collection of CA-MRSA strains evalu-
ated was dominated by strains with PFGE patterns identical or
similar to that of the USA300 strain (94.1% of strains), which
is the predominant endemic/epidemic CA-MRSA clone on the
North American continent. These compounds may be an im-
portant addition to the antimicrobial armamentarium for the
treatment of both community- and hospital-acquired infec-
tions.
This study was funded in part by a research/educational grant from
Cerexa, Inc. (Alameda, CA), a wholly owned subsidiary of Forest
Laboratories, Inc.
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